Share Price and Basic Stock Data
Last Updated: November 10, 2025, 4:44 pm
| PEG Ratio | -0.49 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
EP Biocomposites Ltd operates in the waste management industry, focusing on sustainable solutions. As of the latest reporting period, the company’s share price stood at ₹123, with a market capitalization of ₹20.7 Cr. The company has experienced fluctuating revenue trends over recent quarters. Sales reported for September 2021 were ₹2.76 Cr, which increased to ₹5.30 Cr by March 2022. However, the figure witnessed a decline to ₹3.45 Cr by September 2022 before recovering to ₹4.40 Cr by September 2023. The trailing twelve months (TTM) sales for March 2025 reached ₹12.01 Cr, indicating a significant growth trajectory. The operating profit margin (OPM) showed variability, with a low of 5.91% in September 2023 and a high of 19.43% in March 2022. This inconsistency reflects the challenges the company faces in maintaining steady growth amidst operational fluctuations. Overall, the revenue growth, coupled with the company’s focus on sustainable waste management solutions, positions it favorably within its sector.
Profitability and Efficiency Metrics
EP Biocomposites Ltd has demonstrated mixed profitability metrics over the reporting periods. The net profit for the latest quarter, March 2025, recorded ₹1.03 Cr, with an earnings per share (EPS) of ₹6.13. This reflects a decline from the previous year’s net profit of ₹1.15 Cr for March 2024, showcasing a net profit margin of 8.58%. The company reported a return on equity (ROE) of 10.2% and a return on capital employed (ROCE) of 14.3%, indicating decent efficiency in generating returns relative to shareholder equity and total capital employed. However, the cash conversion cycle (CCC) stood at 298.85 days, which is significantly high and suggests potential inefficiencies in managing working capital. The interest coverage ratio (ICR) of 5.31x indicates the company is comfortably managing its interest obligations, although the declining profitability margins pose a risk to future operations. Overall, while profitability metrics are reasonable, the efficiency challenges may hinder sustainable growth.
Balance Sheet Strength and Financial Ratios
EP Biocomposites Ltd’s balance sheet reflects a growing asset base, with total assets reported at ₹16.63 Cr for March 2025. The company has maintained a conservative leverage level, with total borrowings of ₹2.98 Cr, resulting in a debt-to-equity ratio of 0.28x. The reserves have steadily increased to ₹8.91 Cr, indicating a strengthening equity position. The current ratio stands at 3.95, suggesting ample liquidity to cover short-term liabilities. However, the company’s inventory turnover ratio of 6.52 indicates that inventory is being converted into sales efficiently, yet the high cash conversion cycle raises questions about working capital management. The price-to-book value (P/BV) ratio is reported at 1.96x, which is relatively high compared to typical sector ranges, suggesting that the stock might be overvalued. The overall financial ratios indicate a sound balance sheet, though the company’s operational efficiency could use improvement to enhance financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of EP Biocomposites Ltd reflects a significant degree of promoter control, with promoters holding 70.08% of the total shares as of March 2025. This level of ownership can instill confidence among investors regarding management stability and strategic direction. However, the absence of foreign institutional investors (FIIs) and a low public holding of 29.92% may indicate limited market interest. The number of shareholders has risen to 374, indicating growing investor engagement, although this remains modest compared to larger companies in the sector. The consistent promoter holding over recent quarters suggests a stable governance structure, which might be appealing for long-term investors. Nonetheless, the lack of institutional backing could pose challenges in driving liquidity and broader market acceptance. Investor confidence may hinge on the company’s ability to enhance profitability and operational efficiency going forward.
Outlook, Risks, and Final Insight
Looking ahead, EP Biocomposites Ltd faces both promising opportunities and significant risks. The company’s commitment to sustainable waste management aligns with global trends toward environmental responsibility, which could drive future growth. However, the high cash conversion cycle and fluctuating profitability margins present ongoing challenges that could impact operational efficiency. Additionally, the absence of FIIs may limit access to capital and market support. To bolster investor confidence, the company must focus on improving operational efficiency, enhancing profitability, and maintaining a strong balance sheet. If EP Biocomposites can successfully navigate these challenges while capitalizing on industry trends, it may position itself as a leader in the waste management sector. Conversely, failure to address operational inefficiencies could hinder its growth potential and market reputation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of EP Biocomposites Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| EP Biocomposites Ltd | 17.6 Cr. | 105 | 230/98.0 | 19.2 | 63.5 | 0.00 % | 14.3 % | 10.2 % | 10.0 |
| Eco Recycling Ltd | 1,134 Cr. | 588 | 1,043/502 | 49.7 | 45.6 | 0.00 % | 36.8 % | 84.0 % | 10.0 |
| Antony Waste Handling Cell Ltd | 1,418 Cr. | 501 | 734/460 | 20.5 | 232 | 0.00 % | 12.1 % | 11.3 % | 5.00 |
| Industry Average | 1,276.00 Cr | 398.00 | 29.80 | 113.70 | 0.00% | 21.07% | 35.17% | 8.33 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 5.30 | 3.45 | 3.68 | 4.40 | 7.04 | 4.40 | 7.60 |
| Expenses | 2.42 | 4.27 | 2.92 | 3.26 | 4.14 | 5.90 | 3.91 | 6.31 |
| Operating Profit | 0.34 | 1.03 | 0.53 | 0.42 | 0.26 | 1.14 | 0.49 | 1.29 |
| OPM % | 12.32% | 19.43% | 15.36% | 11.41% | 5.91% | 16.19% | 11.14% | 16.97% |
| Other Income | 0.00 | 0.01 | 0.03 | 0.13 | 0.09 | 0.21 | 0.05 | 0.06 |
| Interest | 0.02 | 0.13 | 0.15 | 0.05 | 0.01 | 0.02 | 0.17 | 0.19 |
| Depreciation | 0.01 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| Profit before tax | 0.31 | 0.85 | 0.36 | 0.45 | 0.29 | 1.28 | 0.32 | 1.10 |
| Tax % | 25.81% | 32.94% | 25.00% | 33.33% | 27.59% | 27.34% | 34.38% | 25.45% |
| Net Profit | 0.24 | 0.57 | 0.27 | 0.30 | 0.22 | 0.93 | 0.21 | 0.83 |
| EPS in Rs | 2.04 | 4.84 | 1.61 | 1.78 | 1.31 | 5.53 | 1.25 | 4.94 |
Last Updated: May 31, 2025, 6:08 am
Below is a detailed analysis of the quarterly data for EP Biocomposites Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 7.60 Cr.. The value appears strong and on an upward trend. It has increased from 4.40 Cr. (Sep 2024) to 7.60 Cr., marking an increase of 3.20 Cr..
- For Expenses, as of Mar 2025, the value is 6.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.91 Cr. (Sep 2024) to 6.31 Cr., marking an increase of 2.40 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.49 Cr. (Sep 2024) to 1.29 Cr., marking an increase of 0.80 Cr..
- For OPM %, as of Mar 2025, the value is 16.97%. The value appears strong and on an upward trend. It has increased from 11.14% (Sep 2024) to 16.97%, marking an increase of 5.83%.
- For Other Income, as of Mar 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.05 Cr. (Sep 2024) to 0.06 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Sep 2024) to 0.19 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.05 Cr. (Sep 2024) to 0.06 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.32 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.78 Cr..
- For Tax %, as of Mar 2025, the value is 25.45%. The value appears to be improving (decreasing) as expected. It has decreased from 34.38% (Sep 2024) to 25.45%, marking a decrease of 8.93%.
- For Net Profit, as of Mar 2025, the value is 0.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Sep 2024) to 0.83 Cr., marking an increase of 0.62 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.94. The value appears strong and on an upward trend. It has increased from 1.25 (Sep 2024) to 4.94, marking an increase of 3.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:24 am
| Metric | Mar 2020n n 3m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 0.57 | 2.95 | 8.06 | 7.12 | 11.43 | 12.01 |
| Expenses | 0.53 | 2.49 | 6.66 | 6.15 | 10.02 | 10.23 |
| Operating Profit | 0.04 | 0.46 | 1.40 | 0.97 | 1.41 | 1.78 |
| OPM % | 7.02% | 15.59% | 17.37% | 13.62% | 12.34% | 14.82% |
| Other Income | 0.00 | 0.00 | 0.02 | 0.17 | 0.30 | 0.11 |
| Interest | 0.00 | 0.00 | 0.19 | 0.23 | 0.04 | 0.36 |
| Depreciation | 0.00 | 0.00 | 0.07 | 0.10 | 0.10 | 0.11 |
| Profit before tax | 0.04 | 0.46 | 1.16 | 0.81 | 1.57 | 1.42 |
| Tax % | 25.00% | 23.91% | 31.03% | 28.40% | 26.75% | 27.46% |
| Net Profit | 0.03 | 0.36 | 0.81 | 0.58 | 1.15 | 1.03 |
| EPS in Rs | 6.00 | 72.00 | 6.88 | 3.45 | 6.84 | 6.13 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 125.00% | -28.40% | 98.28% | -10.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | -153.40% | 126.67% | -108.71% |
EP Biocomposites Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 84% |
| 3 Years: | 14% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 103% |
| 3 Years: | 8% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 11% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:26 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 192.11 | 80.42 | 321.53 | 300.41 | 287.40 | 330.05 |
| Inventory Days | 83.65 | 90.25 | 86.83 | 90.58 | 53.86 | 66.66 |
| Days Payable | 349.79 | 128.35 | 161.90 | 104.79 | 153.74 | 97.87 |
| Cash Conversion Cycle | -74.04 | 42.32 | 246.47 | 286.20 | 187.52 | 298.85 |
| Working Capital Days | -57.63 | 25.98 | 156.69 | 255.81 | 217.47 | 270.79 |
| ROCE % | 219.05% | 41.54% | 13.16% | 15.30% | 14.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 6.13 | 6.84 | 3.94 | 9.48 | 6.97 |
| Diluted EPS (Rs.) | 6.13 | 6.84 | 3.94 | 9.48 | 6.97 |
| Cash EPS (Rs.) | 6.80 | 7.44 | 4.02 | 7.43 | 71.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 63.01 | 56.88 | 50.04 | 16.97 | 77.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 63.01 | 56.88 | 50.04 | 16.97 | 77.30 |
| Revenue From Operations / Share (Rs.) | 71.40 | 68.03 | 42.41 | 68.45 | 589.60 |
| PBDIT / Share (Rs.) | 11.20 | 10.15 | 6.64 | 11.79 | 92.90 |
| PBIT / Share (Rs.) | 10.54 | 9.55 | 6.05 | 11.23 | 92.84 |
| PBT / Share (Rs.) | 8.43 | 9.34 | 4.84 | 9.90 | 92.84 |
| Net Profit / Share (Rs.) | 6.13 | 6.84 | 3.43 | 6.87 | 71.60 |
| PBDIT Margin (%) | 15.69 | 14.91 | 15.65 | 17.22 | 15.75 |
| PBIT Margin (%) | 14.75 | 14.03 | 14.26 | 16.40 | 15.74 |
| PBT Margin (%) | 11.80 | 13.72 | 11.41 | 14.46 | 15.74 |
| Net Profit Margin (%) | 8.58 | 10.04 | 8.07 | 10.04 | 12.14 |
| Return on Networth / Equity (%) | 9.72 | 12.02 | 6.84 | 40.50 | 92.62 |
| Return on Capital Employeed (%) | 13.57 | 15.04 | 10.54 | 31.51 | 120.10 |
| Return On Assets (%) | 6.19 | 7.62 | 4.91 | 8.72 | 27.04 |
| Long Term Debt / Equity (X) | 0.23 | 0.11 | 0.14 | 1.09 | 0.00 |
| Total Debt / Equity (X) | 0.28 | 0.18 | 0.15 | 2.06 | 0.00 |
| Asset Turnover Ratio (%) | 0.75 | 0.85 | 0.67 | 1.52 | 3.14 |
| Current Ratio (X) | 3.95 | 2.84 | 4.45 | 1.69 | 1.39 |
| Quick Ratio (X) | 3.55 | 2.60 | 3.96 | 1.46 | 0.90 |
| Inventory Turnover Ratio (X) | 6.52 | 6.05 | 3.56 | 6.98 | 6.39 |
| Interest Coverage Ratio (X) | 5.31 | 48.88 | 5.50 | 8.89 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 3.91 | 33.94 | 3.84 | 6.18 | 0.00 |
| Enterprise Value (Cr.) | 22.11 | 23.59 | 32.97 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.84 | 2.06 | 4.62 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.74 | 13.83 | 29.53 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.73 | 2.02 | 4.75 | 0.00 | 0.00 |
| Price / BV (X) | 1.96 | 2.41 | 4.03 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.73 | 2.02 | 4.75 | 0.00 | 0.00 |
| EarningsYield | 0.04 | 0.04 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for EP Biocomposites Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 6.80. This value is within the healthy range. It has decreased from 7.44 (Mar 24) to 6.80, marking a decrease of 0.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 63.01. It has increased from 56.88 (Mar 24) to 63.01, marking an increase of 6.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 63.01. It has increased from 56.88 (Mar 24) to 63.01, marking an increase of 6.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.40. It has increased from 68.03 (Mar 24) to 71.40, marking an increase of 3.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.20. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 11.20, marking an increase of 1.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.54. This value is within the healthy range. It has increased from 9.55 (Mar 24) to 10.54, marking an increase of 0.99.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.43. This value is within the healthy range. It has decreased from 9.34 (Mar 24) to 8.43, marking a decrease of 0.91.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.13. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 6.13, marking a decrease of 0.71.
- For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has increased from 14.91 (Mar 24) to 15.69, marking an increase of 0.78.
- For PBIT Margin (%), as of Mar 25, the value is 14.75. This value is within the healthy range. It has increased from 14.03 (Mar 24) to 14.75, marking an increase of 0.72.
- For PBT Margin (%), as of Mar 25, the value is 11.80. This value is within the healthy range. It has decreased from 13.72 (Mar 24) to 11.80, marking a decrease of 1.92.
- For Net Profit Margin (%), as of Mar 25, the value is 8.58. This value is within the healthy range. It has decreased from 10.04 (Mar 24) to 8.58, marking a decrease of 1.46.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.72. This value is below the healthy minimum of 15. It has decreased from 12.02 (Mar 24) to 9.72, marking a decrease of 2.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.57. This value is within the healthy range. It has decreased from 15.04 (Mar 24) to 13.57, marking a decrease of 1.47.
- For Return On Assets (%), as of Mar 25, the value is 6.19. This value is within the healthy range. It has decreased from 7.62 (Mar 24) to 6.19, marking a decrease of 1.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.23, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.28, marking an increase of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has decreased from 0.85 (Mar 24) to 0.75, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 3.95, marking an increase of 1.11.
- For Quick Ratio (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 2. It has increased from 2.60 (Mar 24) to 3.55, marking an increase of 0.95.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from 6.05 (Mar 24) to 6.52, marking an increase of 0.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.31. This value is within the healthy range. It has decreased from 48.88 (Mar 24) to 5.31, marking a decrease of 43.57.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.91. This value is within the healthy range. It has decreased from 33.94 (Mar 24) to 3.91, marking a decrease of 30.03.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22.11. It has decreased from 23.59 (Mar 24) to 22.11, marking a decrease of 1.48.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.84, marking a decrease of 0.22.
- For EV / EBITDA (X), as of Mar 25, the value is 11.74. This value is within the healthy range. It has decreased from 13.83 (Mar 24) to 11.74, marking a decrease of 2.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.73, marking a decrease of 0.29.
- For Price / BV (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has decreased from 2.41 (Mar 24) to 1.96, marking a decrease of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.73, marking a decrease of 0.29.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in EP Biocomposites Ltd:
- Net Profit Margin: 8.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.57% (Industry Average ROCE: 21.07%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.72% (Industry Average ROE: 35.17%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.2 (Industry average Stock P/E: 29.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.58%